[Skip to Content]
[Skip to Content Landing]
Viewpoint
December 2015

The Slippery Slope of Broadening Treatment Eligibility and Weak End PointsDefending the Oligo in Oligometastatic Non–Small-Cell Lung Cancer

Author Affiliations
  • 1Swedish Cancer Institute, Global Resource for Advancing Cancer Education (GRACE), Seattle, Washington
JAMA Oncol. 2015;1(9):1219-1220. doi:10.1001/jamaoncol.2015.2966

The concept of oligometastatic disease extends from that of the precocious metastasis, a clinical setting in which a patient has a focus of metastatic disease that may not be accompanied by widespread micrometastatic disease and therefore may potentially be cured with local therapy to both the primary cancer and an isolated metastatic focus.1 Patients with a single brain or adrenal metastasis from non–small-cell lung cancer (NSCLC) may have a 5-year survival of 25% after resection of both the primary cancer and metastasis,2 vastly exceeding the negligible long-term survival of more widespread metastatic NSCLC. Patients who have undergone resection for limited hepatic metastases from colon cancer3 or of lung metastases from sarcoma and colorectal cancer4 also may demonstrate very prolonged survival.

First Page Preview View Large
First page PDF preview
First page PDF preview
×